Table 9.

Comparison of dichotomous efficacy results for sildenafil, tadalafil, and vardenafil

	Sildenafil (50/100 mg)					Tadalafil (10/20 mg)					Vardenafil (10/20 mg)
	Number of		Percent with			Number of		Percent with			Number of		Percent with
Outcome	Trials	Patients	Sildenafil	Placebo	NNT/NNTp/NNH (95% CI)	Trials	Patients	Tadalafil	Placebo	NNT/NNTp/NNH (95% CI)	Trials	Patients	Vardenafil	Placebo	NNT/NNTp/NNH (95% CI)
Efficacy
Improved erections	29	5467	76	23	1.9 (1.8 to 2.0)	7	1651	75	24	1.9 (1.8 to 2.1)	7	2856	71	22	2.0 (1.9 to 2.2)
Withdrawal
All-cause	30	5562	8	12	23 (17 to 37)	5	1334	13	19	15 (8.8 to 46)	5	2061	20	32	7.7 (6.0 to 11)
Lack of efficacy	30	5463	1.2	4.4	25 (21 to 34)	6	1435	3.3	7.5	24 (14 to 69)	6	2320	4.0	12	11 (9.0 to 16)
Adverse event	31	5787	1.6	0.6	120 (67 to 560)	7	1657	3.4	1.5	52 (29 to 260)	7	2868	3.3	1.8	65 (37 to 250)
Adverse events
All cause	18	2862	50	30	4.9 (4.2 to 6.0)	3	590	47	25	4.6 (3.4 to 7.2)	insufficient data
Serious	17	2591	2.5	2.4	not calculated	7	1655	1.2	1.1	not calculated	5	1984	2.2	3.2	not calculated
Headache	34	6386	17	5.2	8.6 (7.6 to 10)	7	1810	13	3.4	11 (8.5 to 14)	6	2411	15	4.1	9.6 (7.9 to 12)
Dyspepsia	26	4967	7.8	2.3	18 (15 to 23)	6	1401	10	0.2	11 (8.8 to 14)	5	1972	3.8	0.3	31 (22 to 48)
Flushing	33	6363	13	1.9	9.0 (8.1 to 10)	6	1530	4.8	0.2	24 (18 to 38)	5	1984	13	0.8	8.0 (6.9 to 9.6)
Rhinitis	21	4283	5.4	2.1	31 (23 to 47)	2	712	3.1	0.5	not calculated	5	2212	7.9	3.6	23 (16 to 42)

NNT is given in standard font, NNTp in bold, and NNH in bold italic. No NNT/NNTp/NNH was calculated unless there was a statistically significant difference